The George-Huntington-Institute (GHI) is devoted to clinical care and preclinical and clinical research in Huntington's disease. The GHI entertains one of the largest HD out-patient clinics for sympotmatic and premanifest gene carriers, persons at-risk and care-takers around the world. The GHI was founded in 2013 by Dr. Ralf Reilmann in Münster to extend the work initiated by him in 2001 at the University of Münster. The GHI is actively involved in several activities of the European Huntington's Disease Network (EHDN). Dr. Reilmann serves as elected memeber of the EHDN executive committee and the HSG executive committee, and chair of the EHDN motor phenotype working group. In cooperation with Dr. Herwig Lange the team in Münster recruited more than 750 participants in the ENROLL-HD study, is a leading site in recruiting for HD-Clarity and was actively involved in several clinical trials.
More information can be found on this webpage.
To contact us or to ask for an appointment please call: +49-251-788-788-0, send us an email to info (at) ghi-muenster.de or use our contact form. We look forward to hearing from you!
Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021
Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...Read More
PROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020
GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...Read More
SHIELD-HD Study of Triplet Therapeutics started at GHI
September 24, 2020
Erreichbarkeit während der Umzugsphase
June 22, 2020
Liebe Patienten, Angehörige und Interessenten,
aufgrund des Umzugs sind die...Read More
IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019
The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...Read More